α-Conotoxin AuIB (trifluoroacetate salt) (Synonyms: GCCSYPPCFATNPDC) |
カタログ番号GC49097 |
α3β4サブユニットを含むnAChRのコノトキシンおよび拮抗剤
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: N/A
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
α-コノトキシンAuIBは、C. aulicusで発見されたコノトキシンであり、受容体拮抗作用と鎮痛作用があることが報告されています。1 このペプチドは、α3β4サブユニットを含むニコチン性アセチルコリン受容体(nAChRs)の拮抗剤であり(IC50=0.75μM)、α2β2、 α2β4、 α3β2、 α4β‑ ‑ ‑ ‑‑, α1β1γδ サブユニットを含むnAChRsよりも100倍以上選択的です。ただし、同種のα7 nAChRsに対しては3μMで34%阻害します。脊髄内投与することにより、部分的な坐骨神経結紮によるラットの神経障害性疼痛モデルにおいて、α-コノトキシンAuIB(0.2および2 nmol /動物)は機械的な触覚過敏を減少させます。2 また、マウスのモルヒネ離脱モデルにおいて、脳室内投与することにより1.75および3.5 pmol /動物の用量で離脱の身体的兆候を逆転させることが報告されています。3
1. Luo, S., Kulak, J.M., Cartier, G.E. 他、「α-Conotoxin AuIBは選択的にα3β4ニコチン性アセチルコリン受容体とニコチン誘発性ノルエピネフリン放出を阻害する」、J. Neurosci.18(21)8571-8579(1998) 2. Napier, I.A., Klimis, H., Rycroft, B.K. 他、「異なるニコチン受容体サブタイプに作用する脊髄内α-conotoxins Vc1.1、AuIBおよびMIIが神経障害性疼痛の徴候を逆転させる」、Neuropharmacology62(7)2202-2207(2012) 3. Muldoon, P.P., Jackson, K.J., Perez, E. 他、「α3β4*ニコチンACh受容体サブタイプはモルヒネの身体依存を仲介する:マウスおよび人間の研究」、Br.J.Pharmacol.171(16)3845-3857(2014)
Cas No. | N/A | SDF | |
同義語 | GCCSYPPCFATNPDC | ||
Canonical SMILES | O=C1[C@@]2([H])N(CCC2)C([C@@H](NC([C@@H](NC([C@@]3([H])NC([C@H](CSSC[C@@H](C(N[C@H](C(N[C@H](C(N[C@@](C(N[C@H](C(N4[C@](CCC4)([H])C(N[C@H](C(N[C@@H](CSSC3)C(N)=O)=O)CC(O)=O)=O)=O)CC(N)=O)=O)([H])[C@H](O)C)=O)C)=O)CC5=CC=CC=C5)=O)NC([C@@]6([H])N1CCC6)=O)NC(CN)=O)=O)=O)CO)=O)CC7=CC=C(C=C7)O)=O.OC(C(F)(F)F)=O | ||
Formula | C65H89N17O21S4·XCF3COOH | M.Wt | 1572.8 |
溶解度 | Water: 5 mg/ml | Storage | -20°C |
General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. |
Prepare stock solution | |||
1 mg | 5 mg | 10 mg | |
1 mM | 0.6358 mL | 3.179 mL | 6.3581 mL |
5 mM | 0.1272 mL | 0.6358 mL | 1.2716 mL |
10 mM | 0.0636 mL | 0.3179 mL | 0.6358 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Average Rating: 5
(Based on Reviews and 1 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *